Search Results
Apr 13, 2026, 11:16 ET Green Bonds Market to Reach $1,555.1 billion, Globally, by 2033 at 10.1% CAGR: Allied Market Research
regulatory support, well-established sustainability frameworks, and high investor demand for green finance. The European Union's Green Bond Standard (EU GBS) and Sustainable Finance Disclosure Regulation (SFDR) have played a crucial role in promoting transparency and credibility in green bond issuances. Additionally,
More news about: Allied Market Research
Mar 31, 2026, 09:00 ET Encoda and GBS Partner to Deliver Advanced Financial Health Management to Healthcare Organizations
GBS, a comprehensive healthcare technology solutions provider. This collaboration brings Encoda's platform into GBS' hosted environment, strengthening their healthcare technology solutions through Encoda's powerful
More news about: Encoda LLC
Mar 29, 2026, 07:29 ET Goodbaby International 2025 Revenue Reaches Approximately HK$8,659.2 Million
organization structure, which led to improved expense performance in the second half of the year.gb's product portfolio and channel upgrades lead to margin improvementgb's revenue was approximately HK$745.5 million (2024: approximately HK$918.1 million) for the Year. The revenue
More news about: Goodbaby International
Mar 26, 2026, 09:00 ET Happiest Minds and UnifyApps Announce Strategic Partnership to Accelerate Enterprise AI Adoption
Generative AI Business Services Unit (GBS) expertise with UnifyApps AI-Native platform, customers will gain access to end-to-end AI transformation from strategy and use case identification to implementation and managed services. Praveen RP, Co-CEO, GBS, Happiest Minds Technologies, said, "We
More news about: Happiest Minds Technologies Limited
Mar 26, 2026, 03:21 ET Hansa Biopharma publishes 2025 Annual and Sustainability Reports
HNSA-5487Hansa made the strategic decision to advance its next generation enzyme HNSA-5487 into development for Guillain–Barré syndrome (GBS), with FDA interactions planned for first half of 2026.Strengthened Leadership to Support Next Phase of GrowthTo drive execution
More news about: Hansa Biopharma AB
Mar 26, 2026, 03:19 ET Hansa Biopharma publishes 2025 Annual and Sustainability Reports
HNSA-5487Hansa made the strategic decision to advance its next generation enzyme HNSA-5487 into development for Guillain–Barré syndrome (GBS), with FDA interactions planned for first half of 2026.Strengthened Leadership to Support Next Phase of GrowthTo drive execution
More news about: Hansa Biopharma AB
Mar 25, 2026, 20:00 ET Great Place To Work™大中華區慶祝2026年Best Workplaces for Women™
Food Ltd. 上海太太樂食品有限公司SIEMENS Healthineers 西門子醫療Sino-US United MetLife 大都會人壽Sinobiom 聖博瑪Standard Chartered GBS China & GBS Guangzhou 渣打環球商業服務中心Stryker China Commercial / Stryker (Suzhou) Medical Technology Co., Ltd. 史賽克中國 / 史賽克（蘇州）醫療技術有限公司Suntory
More news about: Great Place To Work™
Mar 23, 2026, 08:40 ET ADEC Innovations Wins Service Provider of the Year at SSON Impact Awards 2026
About SSON Impact AwardsThe SSON Impact Awards celebrate excellence across the shared services, GBS, and outsourcing industry. They are hosted by SSON (the Shared Services & Outsourcing Network) across four regions: Europe, North America, Asia,
More news about: ADEC Innovations
Mar 11, 2026, 00:15 ET MaestroWellness 將於3月26日舉辦香港首屆「 Build Well Live Well 」健康高峰會
」健康高峰會加強香港作為區域資本形成與創新樞紐的重要角色。高峰會匯聚各界精英，包括財務管理領袖、風險投資公司及家族辦公室，致力於促進可擴展的健康及長壽方案投資管道。由全球財務運營系統 Finmo 作為主要贊助商，體現財務基建在綜合健康生活系統中的重要性，展示政策、資金與企業協同推動健康長壽產業發展的意義。與會者將有機會與多位全球領袖交流，包括主講嘉賓：香港著名政商界領袖陳智思先生（GBM, GBS, JP），以及擁有逾 120 年歷史的家族企業曹寶記（TPC）第四代掌舵人兼「善經濟聯盟」（AWE）主席曹慰德先生（Frederick Chavalit Tsao）。同場更有安盛集團資深顧問韋國敦先生 （Gordon Watson），聯同全球身心健康倡議者及商業領袖，體現高峰會致力於推動跨界先驅合作的宗旨。其他國際專家包括布吉島康民國際醫院首席執行官
More news about: MaestroWellness
Mar 06, 2026, 08:00 ET Kimberly-Clark Appoints Francesco Tinto as Chief Information & GBS Officer
As Chief Information & GBS Officer, Tinto will lead Kimberly-Clark's Information Technology and GBS organizations. "Francesco brings a rare combination of technology leadership and operational
More news about: Kimberly-Clark Corporation
Mar 06, 2026, 05:55 ET GLOBALE LEADER IM BEREICH TRANSFORMATION IM ADVISORY BOARD VON AOKAH
Erfahrene Führungskräfte aus den Bereichen GBS, Finanzen und Transformation verstärken Aokahs AI + Expert Orchestration PlatformNEW YORK, 6. März 2026 /PRNewswire/ -- Aokah, die AI + Expert Intelligence
More news about: Aokah Inc
Mar 06, 2026, 02:01 ET DES LEADERS DE LA TRANSFORMATION MONDIALE INTÈGRENT LE CONSEIL CONSULTATIF D'AOKAH
Des cadres chevronnés de GBS, Finance et Transformation renforcent la plateforme d'orchestration IA + Expert d'AokahNEW YORK, 6 mars 2026 /PRNewswire/ -- Aokah, la plateforme d'intelligence et d'orchestration
More news about: Aokah Inc
Mar 05, 2026, 22:30 ET GLOBAL TRANSFORMATION LEADERS JOIN AOKAH ADVISORY BOARD
Seasoned GBS, Finance, and Transformation Executives Strengthen Aokah's AI + Expert Orchestration PlatformNEW YORK, March 6, 2026 /PRNewswire/ -- Aokah, the AI + Expert Intelligence and Orchestration Platform
More news about: Aokah Inc
Mar 05, 2026, 22:30 ET Líderes de transformación global se unen al consejo asesor de Aokah
Ejecutivos con amplia experiencia en GBS, finanzas y transformación fortalecen la plataforma de IA y orquestación experta de Aokah.NUEVA YORK, 6 de marzo de 2026 /PRNewswire/ -- Aokah, la plataforma de
More news about: Aokah Inc
Mar 05, 2026, 09:00 ET GLOBAL TRANSFORMATION LEADERS JOIN AOKAH ADVISORY BOARD
Seasoned GBS, Finance, and Transformation Executives Strengthen Aokah's AI + Expert Orchestration PlatformNEW YORK, March 5, 2026 /PRNewswire/ -- Aokah, the AI + Expert Intelligence and Orchestration Platform
More news about: Aokah Inc
Mar 04, 2026, 18:27 ET PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA.
More news about: Hansa Biopharma AB
Mar 04, 2026, 18:25 ET PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA.
More news about: Hansa Biopharma AB
Feb 24, 2026, 08:00 ET Beta-Lactam Allergy Delabeling Safe for Pregnant Patients
Evaluation of penicillin allergy labels in pregnancy reduces beta-lactam alternative antibiotic use in GBS-positive patientsMILWAUKEE, Feb. 24, 2026 /PRNewswire/ -- Penicillin allergy evaluation
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 18, 2026, 14:30 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA.
More news about: Hansa Biopharma AB
Feb 18, 2026, 14:28 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA.
More news about: Hansa Biopharma AB
Feb 18, 2026, 09:30 ET Global X Launches Two New Options-Based ETFs Targeting Weekly Distributions
and the Global X U.S. 500 Income EdgeSM ETF (EDGX). These actively managed funds provide exposure to the Nasdaq-100 Index and the Solactive GBS United States 500 Index, respectively.
More news about: Global X Management Company LLC
Feb 12, 2026, 09:00 ET Beta-Lactam Allergy Delabeling Safe for Pregnant Patients
Evaluation of penicillin allergy labels in pregnancy reduces beta-lactam alternative antibiotic use in GBS-positive patientsMILWAUKEE, Feb. 12, 2026 /PRNewswire/ -- Penicillin allergy evaluation
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 11, 2026, 01:34 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
vector. No severe side effects were reported.HNSA-5487: Hansa is advancing the next-generation enzyme, HNSA-5487, in Guillain-Barré syndrome (GBS). The company is planning for FDA interactions in the first half of 2026, to reach agreement on the clinical development program.Financial
More news about: Hansa Biopharma AB
Feb 11, 2026, 01:29 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
vector. No severe side effects were reported.HNSA-5487: Hansa is advancing the next-generation enzyme, HNSA-5487, in Guillain-Barré syndrome (GBS). The company is planning for FDA interactions in the first half of 2026, to reach agreement on the clinical development program.Financial
More news about: Hansa Biopharma AB
Jan 28, 2026, 10:15 ET Robotic Process Automation Market to Reach USD 20.79 Billion by 2032 as Enterprises Redesign AI-Driven Operating Models: MMR Statistics
Kingdom, Europe, APAC High-Impact Industries: BFSI, Healthcare & Life Sciences, Manufacturing, Telecom, Global Business Services (GBS) From Task Automation to Enterprise Execution Control What distinguishes the current cycle of the Robotic Process Automation
More news about: Maximize Market Research Pvt. Ltd.